What's new

Human medicines European public assessment report (EPAR): Azacitidine Mylan, azacitidine, Date of authorisation: 27/03/2020, Revision: 8, Status: Authorised

Human medicines European public assessment report (EPAR): Azacitidine Mylan, azacitidine, Date of authorisation: 27/03/2020, Revision: 8, Status: Authorised

Apr 7, 2025 - 14:23
 0
Human medicines European public assessment report (EPAR): Azacitidine Mylan, azacitidine, Date of authorisation: 27/03/2020, Revision: 8, Status: Authorised
Human medicines European public assessment report (EPAR): Azacitidine Mylan, azacitidine, Date of authorisation: 27/03/2020, Revision: 8, Status: Authorised
Read More

Tags:

Previous Article

‘A new normal’ after another measles death?

Next Article

Shein denies ‘cutting corners’ on labour practices

Related Posts

Herbal medicinal product: Carvi aetheroleum, Carum carvi L., F: Assessment finalised

Herbal medicinal product: Carvi aetheroleum, Carum carv...

Apr 1, 2025  0

Opinion/decision on a Paediatric investigation plan (PIP): Litfulo, Ritlecitinib, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Skin and subcutaneous tissue disorders, PIP number: P/0026/2024

Opinion/decision on a Paediatric investigation plan (PI...

Mar 14, 2025  0

Human medicines European public assessment report (EPAR): Prasugrel Viatris (previously Prasugrel Mylan), prasugrel, Date of authorisation: 15/05/2018, Revision: 11, Status: Authorised

Human medicines European public assessment report (EPAR...

Mar 25, 2025  0